A stark difference in the profiles of defective viral transcripts between SARS-CoV-2 and SARS-CoV

Xie, Dongying; Chu, Hin; Yang, Dong; Ding, Qiutao; Huang, Gefei; Luo, Chen; Cai, Zongwei; Huang, Jian‐Dong; Zhao, Zhongying

doi:10.1016/j.jinf.2021.06.020

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomarkers are defined as “objectively measured and evaluated characteristics that serve as indicators of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions.” Biomarkers provide knowledge and guidance for clinical pharmacology and play diagnostic, prognostic, and predictive roles. [ 5 ] Many studies have shown that there is a correlation between the clinical severity and strains of COVID-19 and certain biomarkers, [ 6 ] which means that the strains or detection rate of viruses can be predicted by biochemical indicators. However, when these related studies [ 7 ] selected their control group, they mainly selected cases that were nucleic acid-negative but were suspected cases or non-COVID-19 cases.…”

Section: Introductionmentioning

confidence: 99%

Logistic regression analysis of the value of biomarkers, clinical symptoms, and imaging examinations in COVID-19 for SARS-CoV-2 nucleic acid detection

Huang,

Zhang,

et al. 2024

Medicine

View full text Add to dashboard Cite

The detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) nucleic acid detection provides a direct basis for diagnosing Coronavirus Disease 2019. However, nucleic acid test false-negative results are common in practice and may lead to missed diagnosis. Certain biomarkers, clinical symptoms, and imaging examinations are related to SARS-CoV-2 nucleic acid detection and potential predictors. We examined nucleic acid test results, biomarkers, clinical symptoms, and imaging examination data for 116 confirmed cases and asymptomatic infections in Zhuhai, China. Patients were divided into nucleic acid-positive and -false-negative groups. Predictive values of biomarkers, symptoms, and imaging for the nucleic acid-positive rate were calculated by Least Absolute Shrinkage and Selection Operators regression analysis and binary logistic regression analysis, and areas under the curve of these indicators were calculated. Hemoglobin (OR = 1.018, 95% CI: 1.006–1.030; P = .004) was higher in the respiratory tract-positive group than the nucleic acid-negative group, but platelets (OR = 0.996, 95% CI: 0.993–0.999; P = .021) and eosinophils (OR = 0.013, 95% CI: 0.001–0.253; P = .004) were lower; areas under the curve were 0.563, 0.614, and 0.642, respectively. Some biomarkers can predict SARS-CoV-2 viral nucleic acid detection rates in Coronavirus Disease 2019 and are potential auxiliary diagnostic tests.

show abstract

Section: Introductionmentioning

confidence: 99%

Logistic regression analysis of the value of biomarkers, clinical symptoms, and imaging examinations in COVID-19 for SARS-CoV-2 nucleic acid detection

Huang,

Zhang,

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

Relevant SARS‐CoV‐2 viremia is associated with COVID‐19 severity: Prospective cohort study and validation cohort

Domingo

Roy-Vallejo

Cruz

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Background Early Kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative RT‐PCR was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Methods Prospective observational single‐centre study including consecutive adult patients hospitalised with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU) and their combination (Poor Outcome). Relevant Viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalised COVID‐19 patients from April 2021‐May 2022, in which plasma samples were collected according to clinical criteria. Results Prospective cohort: 57 patients were included. RV was defined as at least a two‐fold increase in VL within ≤2 days or a VL>300 copies/mL, in the first week. Patients with RV (N=14; 24.6%) were more likely to die than those without RV (35.7% vs 0%), needed ICU admission (57% vs 0%) or had Poor Outcome (71.4% vs 0%), (p<0.001 for the three variables) Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission [OR 5.6 (95%CI,2.1‐15.1); p=0.001], mortality [OR 13.5 (95%CI,6.3‐28.7); p<0.0001] and Poor Outcome [OR 11.2 (95%CI,5.8‐22); p<0.0001] Conclusion Relevant SARS‐CoV‐2 viremia in the first week of hospitalisation was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort. This article is protected by copyright. All rights reserved.

show abstract

A stark difference in the profiles of defective viral transcripts between SARS-CoV-2 and SARS-CoV

Cited by 2 publications

References 9 publications

Logistic regression analysis of the value of biomarkers, clinical symptoms, and imaging examinations in COVID-19 for SARS-CoV-2 nucleic acid detection

Logistic regression analysis of the value of biomarkers, clinical symptoms, and imaging examinations in COVID-19 for SARS-CoV-2 nucleic acid detection

Relevant SARS‐CoV‐2 viremia is associated with COVID‐19 severity: Prospective cohort study and validation cohort

Contact Info

Product

Resources

About